@FierceBiotech: Hear from top execs at Janssen talk about drug R&D, industry's drug pipeline efforts. More | Follow @FierceBiotech
@RyanMFierce: Biotech rattled as Q1 first-time VC deals plunge to 18-year low. News | Follow @RyanMFierce
> Finnish drugmaker Orion rallied on news of increased cashflow from partnerships. Article
> Fast-moving Pharmacyclics ($PCYC) wrapped up enrollment of a Phase III trial for its closely watched cancer drug ibrutinib, which the FDA has given "Breakthrough Therapy" status. Item
@FierceMedDev: Hamburg: FDA is a bargain for taxpayers. Story | Follow @FierceMedDev
@DamianFierce: LabCorp is slimming down and diversifying to stay profitable in a tough testing market. More | Follow @DamianFierce
> Intuitive Surgical's Q1 soars, despite da Vinci robot lawsuits. Article
> Covidien recalls ventilator batteries over failure risk. More
> Device company VC funding continues its plunge. Report
Pharma News
@FiercePharma: U.K. likely to pay for Avastin despite another NICE rejection. More | Follow @FiercePharma
@EricPFierce: Some popular drugs like Pradaxa, Prolia to be put through despised German price shredding formula. Story | Follow @EricPFierce
> Russia tells Abbott no-go on buyout of partner Petrovax. Article
> U.K. goes after GSK for decade-old pay-for-delay deal. Story
And Finally… The NCI is investing in a study of "exceptional responders" from failed cancer drug trials to learn why those patients benefited. Article